Seres Therapeutics, Inc. (MCRB)
2.94
+0.01
(+0.34%)
USD |
NASDAQ |
Oct 02, 16:00
2.93
-0.01
(-0.34%)
After-Hours: 20:00
Seres Therapeutics Net Income (Quarterly) : 4.581M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.581M |
| March 31, 2026 | -19.91M |
| December 31, 2025 | -15.34M |
| September 30, 2025 | 8.204M |
| June 30, 2025 | -19.86M |
| March 31, 2025 | 32.68M |
| December 31, 2024 | -15.64M |
| September 30, 2024 | -51.04M |
| June 30, 2024 | -26.20M |
| March 31, 2024 | -32.90M |
| December 31, 2023 | -34.72M |
| September 30, 2023 | -41.02M |
| June 30, 2023 | 46.55M |
| March 31, 2023 | -71.17M |
| December 31, 2022 | -68.80M |
| September 30, 2022 | -60.00M |
| June 30, 2022 | -64.74M |
| March 31, 2022 | -56.62M |
| December 31, 2021 | -50.00M |
| September 30, 2021 | 68.22M |
| June 30, 2021 | -48.33M |
| March 31, 2021 | -35.46M |
| December 31, 2020 | -18.25M |
| September 30, 2020 | -30.28M |
| Date | Value |
|---|---|
| June 30, 2020 | -20.71M |
| March 31, 2020 | -19.88M |
| December 31, 2019 | -18.78M |
| September 30, 2019 | -16.41M |
| June 30, 2019 | -10.76M |
| March 31, 2019 | -24.33M |
| December 31, 2018 | -21.29M |
| September 30, 2018 | -21.95M |
| June 30, 2018 | -27.79M |
| March 31, 2018 | -27.92M |
| December 31, 2017 | -28.95M |
| September 30, 2017 | -6.935M |
| June 30, 2017 | -28.02M |
| March 31, 2017 | -25.47M |
| December 31, 2016 | -25.28M |
| September 30, 2016 | -18.69M |
| June 30, 2016 | -27.91M |
| March 31, 2016 | -19.70M |
| December 31, 2015 | -19.63M |
| September 30, 2015 | -14.62M |
| June 30, 2015 | -12.56M |
| March 31, 2015 | -7.971M |
| March 31, 2014 | -1.689M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
| Curis, Inc. | -8.581M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.736M |
| Total Expenses (Quarterly) | -3.845M |
| EPS Diluted (Quarterly) | 0.47 |
| Enterprise Value | 69.94M |
| Gross Profit Margin (Quarterly) | 8.97% |
| Earnings Yield | -77.46% |
| Normalized Earnings Yield | -60.53 |